The AJMC® Atopic Dermatitis compendium is a comprehensive resource for clinical news and expert insights for the chronic skin condition that typically develops in early childhood.
Study Examines Dupilumab's Effect on EoE When Given for AD, Other Conditions
Administering dupilumab for other atopic conditions, including atopic dermatitis (AD) and asthma, in patients who also have eosinophilic esophagitis (EoE), resulted in improved EoE symptoms.
Skin Barrier Function in Moderate to Severe AD Significantly Improved With Dupilumab
Dupilumab was shown to significantly improve factors of skin barrier function, including transepidermal water loss, lipid composition, and filaggrin, among patients with moderate to severe atopic dermatitis.
Multidisciplinary Approach Identifies Allergic, Immunology Burden in Severe AD
Patients with severe atopic dermatitis showed significant associations with concomitant contact dermatitis and immune dysfunction after undergoing a multidisciplinary evaluation between allergy, immunology, and dermatology specialists.
Significant Disease Burden Found in Children With Moderate to Severe AD
Uncontrolled disease burden was a major unmet need among children with moderate to severe atopic dermatitis (AD) who were unresponsive to topical therapies.
Worse Health-Related QOL, Mental Health in Patients With AD During the Pandemic
Polish patients with atopic dermatitis reported lower overall health and impaired quality of life related to mental health in the first year of the COVID-19 pandemic.
Dr Robert Sidbury Discusses Utilization, Efficacy of Biologics for Atopic Dermatitis
Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital, speaks on the efficacy of biologics in the treatment of atopic dermatitis and other recently approved therapeutics.
Dr Robert Sidbury on Risk Factors, Diagnosis of Atopic Dermatitis
Robert Sidbury, MD, MPH, chief of the Division of Dermatology at Seattle Children's Hospital, discusses risk factors involved in the pathogenesis of atopic dermatitis and several diagnostic methods.
Jobs in Forestry, Agriculture Linked With Increased AD Risk in Workers' Children
Japanese children of parents whose family business was primarily industry, including agriculture, forestry, and fisheries, had a greater risk of atopic dermatitis (AD) development.
AD Severity Linked With Sleep, Attention Issues in Young Children
Children with moderate to severe atopic dermatitis were found to be more likely to report suboptimal sleep and attention regulation outcomes.
Dr Robert Sidbury Explains Pathophysiology, Comorbidity Risk of Atopic Dermatitis
Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital, speaks on the inflammatory mechanisms of atopic dermatitis and risk of comorbidities in affected patients.
FDA Approves Abrocitinib for Adults With Moderate to Severe Atopic Dermatitis
The JAK1 inhibitor abrocitinib (Cibinqo) was recently approved by the FDA for the treatment of adults with refractory, moderate to severe atopic dermatitis.
Social Determinants May Influence Health Care Utilization, Symptom Burden in Patients With Asthma and Eczema
Minority patients and those with low income were more likely than White and high-income counterparts to report adverse outcomes in the management of asthma and eczema.
Understanding, Managing Flares in Atopic Dermatitis
Researchers review current knowledge on the management of flares in atopic dermatitis, including treatment and unmet needs.
Dupilumab Significantly Reduces Hospitalization Rates in Patients With Atopic Dermatitis
Patients with atopic dermatitis (AD) treated with dupilumab showed reduced hospitalization rates and shorter duration of AD-related hospitalizations vs those treated with control therapies.
Substantial Cost Burden, Health Care Utilization Found in Patients With Severe Atopic Dermatitis
Patients with atopic dermatitis were associated with significant economic burden primarily driven by outpatient visits and pharmacy use, which increased with disease severity.
Early-Life Infection Linked With Atopic Dermatitis Development in Infants, Children
Incidence of infectious diseases, skin infections, and systemic antibiotic exposure were all associated with the development of atopic dermatitis among infants and young children.
Greater Risk of COVID-19 Infection Found in Patients With Atopic Dermatitis
Patients with atopic dermatitis were shown to be more likely to receive a COVID-19 diagnosis than the general population.
Atopic Dermatitis Associated With Behavioral Issues in Children and Adolescents
Children and adolescents with atopic dermatitis (AD) tended to have a higher number of delinquent behaviors than those without AD, including fighting, cheating on exams, and suspension.
Real-World Study Finds Dupilumab Safe, Effective for Moderate-to-Severe Atopic Dermatitis
Korean patients with moderate-to-severe atopic dermatitis achieved and maintained markedly improved skin clearance with dupilumab treatment in a real-world setting, including in the face and hands.
Dr David R. Stukus Spotlights Unmet Needs in Atopic Dermatitis Management
David R. Stukus, MD, FACAAI, of Nationwide Children's Hospital and The Ohio State University College of Medicine, and a board member of the American College of Allergy, Asthma & Immunology, speaks on the lack of interventions to manage the underlying causes of exacerbation in atopic dermatitis.
Evaluating Differences in Therapeutic, Diagnostic Approaches to Atopic Dermatitis
A study found significant differences in the therapeutic and diagnostic approaches to atopic dermatitis used by allergists, dermatologists, and pediatricians, and those recommended by guidelines.
Dr David R. Stukus Discusses Access, Affordability Concerns of Emerging Atopic Dermatitis Therapies
David R. Stukus, MD, FACAAI, of Nationwide Children's Hospital and The Ohio State University College of Medicine, and a board member of the American College of Allergy, Asthma & Immunology, speaks on the difficulties of gaining coverage for newer biologic therapies in the treatment of atopic dermatitis.
Dupilumab Shows High Effectiveness in AD for Ages 6 Months and Up
Research presented at the Revolutionizing Atopic Dermatitis (RAD) Virtual Conference said dupilumab (Dupixent) is an effective and safe therapeutic option in adults, adolescents aged 6 to 11 years, and young children aged 6 months to 5 years with moderate-to-severe atopic dermatitis.
Dr David R. Stukus on Immune-Related Response to Therapy in Atopic Dermatitis
David R. Stukus, MD, FACAAI, of Nationwide Children's Hospital and The Ohio State University College of Medicine, and a board member of the American College of Allergy, Asthma & Immunology, discusses efforts to align novel treatments for atopic dermatitis with patients based on the underlying mechanisms of disease.
Many Questions Remain in Deciphering, Preventing Atopic March
In a new review article, investigators outline the challenges to studying the disease, but also point to big data as an important tool moving forward.
Patients With Atopic Dermatitis More Prone to Depression, Anxiety
Patients with atopic dermatitis, particularly those with more severe skin manifestations, were shown to be at greater risk of depression and anxiety compared with the general population.
Increased Risk of Fracture Found in Children With Atopic Dermatitis
Children with atopic dermatitis were shown to be at an increased risk of fractures compared with the general population, with systemic use of corticosteroid and antihistamine therapy cited as mediating factors.
Higher Risk of Systemic, Psychiatric Conditions Found in Patients With Atopic Dermatitis
A high comorbidity burden, including psychiatric, autoimmune, and systemic conditions, was found in US adult ambulatory populations with atopic dermatitis.
Dupilumab-Induced Ophthalmic Disease Common in Adults With Atopic Dermatitis
More than 1 in 3 patients with atopic dermatitis reported incidence of dupilumab-induced ocular surface disease (DIOSD), with asthma and family history of AD shown to further increase the risk of developing DIOSD.
Atopic Dermatitis Severity, Age at Diagnosis May Increase Risk of Ophthalmic Diseases
Moderate-to-severe disease, childhood onset, and systemic treatments were all associated with a greater risk of conjunctivitis in patients with atopic dermatitis, whereas use of soft and hard contact lenses were linked with risk of keratitis.
2 Clarke Drive Cranbury, NJ 08512